Syndax Pharmaceuticals, Inc. (SNDX) Stock

Syndax Pharmaceuticals, Inc. (SNDX) is a Healthcare stock trading at $19.00 (as of 2026-06-18), with a market capitalization of $1.74B and a trailing P/E of -7.0. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Syndax Pharmaceuticals, Inc. develops biopharmaceutical therapies for cancer and related conditions, including SNDX-5613 for MLL-rearranged and NPM1c acute myeloid leukemia and SNDX-6352 (axatilimab) for chronic graft versus host disease. It also develops Entinostat and conducts clinical and research collaborations with organizations including the National Cancer Institute and the Eastern Cooperative Oncology Group.

Valuation — source: SEC EDGAR (first-party)
Price	$19.00
Market Cap	$1.74B
P/E Ratio	-7.0
EV / EBITDA	-9.1
Price / Book	41.71
Price / Sales	7.99
DCF Value (model)	$-64.75
DCF Upside vs Price	-440.8%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$172.35M
Net Margin	-165.6%
Return on Equity	-584.4%
Debt / Equity	8.26
Current Ratio	5.47
Revenue Growth (YoY)	627.8%
EPS Growth (YoY)	-11.6%
FCF Growth (YoY)	17.6%

Financial Health — source: SEC EDGAR
Altman Z-Score	-2.27 (distress)

Valuation vs Sector & Industry
Stock P/E	-7.0
Sector P/E (Healthcare)	21.0
Industry P/E (Pharmaceutical Products)	17.3
vs Sector	-133.5%
vs Industry	-140.7%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	BlackRock, Inc. ($192.82M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Michael A. Metzger
Employees	270
Country	US
IPO Date	2016-03-02

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.